GlaxoSmithKline has been granted approval in the USA to market itsselective serotonin reuptake inhibitor Paxil (paroxetine) for the treatment of generalized anxiety disorder. Paxil is the first SSRI to be approved for this indication in the USA, which is estimated to have a population of around 10 million GAD sufferers. Paxil is already indicated for the treatment of depression, panic disorder, obsessive compulsive disorder and social anxiety disorder, and achieved sales of L1.5 billion ($2.2 billion) in 2000.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze